Ph3 study of Xaluritamig monotherapy with met Castration resistant prostate cancer
Phase III Clinical Trial
AMG509 20230239: A Phase 3 Open-label Multicenter Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer
Participating Locations